Canada Markets close in 4 mins

CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.5025+0.3025 (+7.20%)
As of 03:56PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close4.2000
Open4.2500
Bid4.6000 x 900
Ask4.6100 x 1100
Day's Range4.2200 - 4.6057
52 Week Range1.4300 - 5.7600
Volume3,147,035
Avg. Volume6,366,976
Market Cap435.358M
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)-0.9020
Earnings DateMar 15, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.28
  • Motley Fool

    Why CTI Biopharma Stock Is Surging Today

    Shares of CTI BioPharma (NASDAQ: CTIC) moved sharply higher after the drugmaker reported first-quarter results Friday morning. Investors were pleased with the initial sales figures for Vonjo, its first approved drug, and pushed the stock price 20.8% higher as of 11:22 a.m. ET. On March 1, 2022, the FDA approved Vonjo to treat patients with myelofibrosis, a rare bone marrow disorder.

  • Zacks

    CTI BioPharma (CTIC) Reports Q1 Loss, Tops Revenue Estimates

    CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5.71% and 6.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Zacks

    CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates

    CTI BioPharma (CTIC) delivered earnings and revenue surprises of -35.71% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?